The important announcements for Hong Kong stocks yesterday are as follows:

Company news

$XPENG-W (09868.HK)$: Signed a strategic cooperation framework agreement with Volkswagen Group on electronic and electrical architecture technology. The two sides will jointly develop an electronic and electrical architecture based on Xiaopeng Motor's latest generation electronic and electrical architecture, and it is expected that it will be applied to Volkswagen brand electric models manufactured in China from 2026.

$CHINA TIANRUI (01252.HK)$: Some of the company's shares held by the controlling shareholder were forcibly sold, and trading continued to be suspended.

Financial data

$CNBM (03323.HK)$: The net loss for the first quarter is expected to be 1.3 billion yuan, an increase of 147% over the previous year. Mainly due to the drop in sales prices of cement, concrete and other products.

$SANDS CHINA LTD (01928.HK)$: According to US GAAP, Sands China's total net income for the first quarter of 2024 increased by 42% from the first quarter of 2023 to US$1.8 billion. Sands China's net revenue for the first quarter of 2024 was US$297 million, while the first quarter of 2023 had a net loss of US$10 million.

$ZGC TEC LEASING (01601.HK)$: The first quarter achieved revenue of 207 million yuan, up 8.51% year on year; net profit of 67.1359 million yuan, up 20.59% year on year.

Operational data

$ANTA SPORTS (02020.HK)$: In the first quarter, retail sales of the Anta brand achieved a positive year-on-year increase in the number of units; retail sales of the FILA brand achieved a positive year-on-year increase in the number of units; retail sales of other brands increased 25-30% year over year.

$SUNSHINE INS (06963.HK)$: In the first quarter, Sunshine Financial Insurance and Sunshine Life received original premium income of 12.429 billion yuan and 32.563 billion yuan respectively, up 18.26% and 5.43% year-on-year respectively.

Pharmaceutical Innovation

$IMMUNEONCO-B (01541.HK)$: IMM01 (tidapecip) was approved by the State Drug Administration to conduct a phase III clinical trial plan.

$FOSUN PHARMA (02196.HK)$: Fu Hong Hanlin was approved for drug clinical trials.

$FOSUN PHARMA (02196.HK)$: The application for registration of sodium phosphonate injection was accepted by the State Drug Administration.

Increase or decrease holdings

$DONGFENG GROUP (00489.HK)$: The controlling shareholder Dongfeng Motor Company increased its H share holdings by 3.16 million shares.

Buyback News

$HBM HOLDINGS-B (02142.HK)$: Chairman of the Board Dr. Wang Jinsong has voluntarily promised not to sell any shares in the company directly or indirectly owned by him for at least six months.

$HSBC HOLDINGS (00005.HK)$: HK$226 million was spent to repurchase 3.6 million shares at a repurchase price of HK$62.25-63.05.

$HANG SENG BANK (00011.HK)$: Spend HK$574.276 million to repurchase 600,000 shares at a repurchase price of HK$94.95-96.65.

$CSPC PHARMA (01093.HK)$: Spend HK$349.292 million to repurchase 6 million shares, with a repurchase price of HK$5.77-5.87 per share.

$CK ASSET (01113.HK)$: Approximately HK$26.2594 million was spent to repurchase 839,500 shares at a repurchase price of HK$31.25-31.35.

$KUAISHOU-W (01024.HK)$: Spend HK$1996.25 million to repurchase 435,000 shares at a repurchase price of HK$45.15-47.05.

$SWIRE PACIFIC A (00019.HK)$: Approximately HK$18.730,900 was spent to repurchase 309,000 shares at a repurchase price of HK$9.76-9.85.

$SIMCERE PHARMA (02096.HK)$: A repurchase of 3.288,000 shares was spent at HK$16.948,200, at a repurchase price of HK$5.1-5.2.

editor/tolk